Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE007 (JPN) (Dr. Dubois)
· consented 2023-07-09
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-10-01 (study day 76); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-02-24 (study day 222); relationship: N
mild
assessed
2026-08-18
Grade 1 Peripheral neuropathy — outcome: UNKNOWN; onset 2024-04-08 (study day 266); relationship: N
moderate
assessed
2026-08-18
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-05-01 (study day 289); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-06-18 (study day 337); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-07-11 (study day 360); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.